Advertisement
Advertisement
SLGL
Sol-Gel Technologies Ltd. Ordinary Shares
73.05
USDSponsored
+5.84
+8.69%
May 13, 16:00 UTC -4
Closed
After-Market
73.00
-0.05
-0.06%
SLGL Earnings Reports
Positive Surprise Ratio
SLGL beat 21 of 30 last estimates.
70%
Next Report
Date of Next Report
May 21, 2026
Estimate for Q1 26 (Revenue/ EPS)
$918.00K
/-$1.87
Implied change from Q4 25 (Revenue/ EPS)
+31.90%
/+74.77%
Implied change from Q1 25 (Revenue/ EPS)
--
/--
Sol-Gel Technologies Ltd. Ordinary Shares earnings per share and revenue
On Mar 19, 2026, SLGL reported earnings of -1.07 USD per share (EPS) for Q4 25, missing the estimate of 0.39 USD, resulting in a -368.98% surprise. Revenue reached 696.00 thousand, compared to an expected 6.63 million, with a -89.50% difference. The market reacted with a +20.86% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -1.87 USD, with revenue projected to reach 918.00 thousand USD, implying an increase of 74.77% EPS, and increase of 31.90% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Taysha Gene Therapies, Inc. Common Stock
Report Date
May 06, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.12
Surprise
-20.48%
Amphastar Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.71
Actual
$0.42
Surprise
-41.59%
Personalis, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-5.42%
Assembly Biosciences, Inc
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.58
Actual
-$0.54
Surprise
+7.12%
Teva Pharmaceutical Industries Limited - ADR
Report Date
Apr 29, 2026 For Q1 26
Estimate
$0.48
Actual
$0.53
Surprise
+8.78%
BridgeBio Pharma, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.69
Actual
-$0.84
Surprise
-21.37%
Dr. Reddy's Laboratories Limited - ADR
Report Date
May 12, 2026 For Q4 26
Estimate
$11.40
Actual
$5.73
Surprise
-49.68%
Supernus Pharmaceuticals, Inc.
Report Date
May 05, 2026 For Q1 26
Estimate
$0.30
Actual
$0.60
Surprise
+97.69%
Bausch Health Companies Inc
Report Date
Apr 29, 2026 For Q1 26
Estimate
$0.69
Actual
$0.78
Surprise
+12.33%
FAQ
What were Sol-Gel Technologies Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Sol-Gel Technologies Ltd. Ordinary Shares reported EPS of -$1.07, missing estimates by -368.98%, and revenue of $696.00K, -89.5% below expectations.
How did the market react to Sol-Gel Technologies Ltd. Ordinary Shares's Q4 2025 earnings?
The stock price moved up 20.86%, changed from $66.20 before the earnings release to $80.01 the day after.
When is Sol-Gel Technologies Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for May 21, 2026.
What are the forecasts for Sol-Gel Technologies Ltd. Ordinary Shares's next earnings report?
Based on 3
analysts, Sol-Gel Technologies Ltd. Ordinary Shares is expected to report EPS of -$1.87 and revenue of $918.00K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement